Hosted on MSN1h
Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report?
Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering Biogen Inc. (BIIB), which belongs to the Zacks ...
Hosted on MSN2h
Biotech Stock Roundup: SAGE Up on Declining BIIB's Offer, CYTK, AKRO Up on Updates
It was a busy week for the biotech sector, with regulatory and pipeline updates. Sage Therapeutics SAGE was in focus after it ...
PMLiVE7h
Biogen’s higher dose spinal muscular atrophy regimen accepted for review by EMA/FDA
Biogen has announced that the European Medicines Agency (EMA) and US Food and Drug Administration (FDA) have started ...
Biogen (BIIB) Gets a Buy from RBC Capital
In a report released today, Brian Abrahams from RBC Capital maintained a Buy rating on Biogen (BIIB – Research Report), with a price target of ...
BioSpace8h
RFK Jr. Faces the Senate, Sage Rebuffs Biogen, Obesity Space Expands, More
Donald Trump continues to make waves in biopharma; Sage rejects Biogen’s unsolicited takeover offer; the obesity space sees ...
marketinference8h
Sage Therapeutics Rejects Biogen's Acquisition Proposal
While the strategic review process is underway, Sage Therapeutics continues to advance its mission of pioneering solutions to ...
Sage Therapeutics Initiates Strategic Review Process and Rejects Proposal from Biogen
Sage Therapeutics, Inc. filed an 8-K report with the Securities and Exchange Commission. The filing disclosed that the Board of Directors of Sage Therapeutics has commenced a strategic review process ...
Biogen Inc. stock underperforms Tuesday when compared to competitors
The stock's fall snapped a five-day winning streak.
devdiscourse23h
From Drug Approvals to Global Health Funding: Key Updates in Health Sector
This article highlights recent developments in healthcare, including the U.S. FDA's approval of Alzheimer's and diabetes ...